Anish Patel - Feb 6, 2024 Form 4 Insider Report for Enliven Therapeutics, Inc. (ELVN)

Signature
/s/ Ben Hohl, by power of attorney
Stock symbol
ELVN
Transactions as of
Feb 6, 2024
Transactions value $
-$73,658
Form type
4
Date filed
2/8/2024, 08:47 PM
Previous filing
Jan 24, 2024
Next filing
Feb 15, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ELVN Common Stock Sale -$73.7K -4.88K -28.31% $15.11 12.3K Feb 6, 2024 Direct F1, F2
holding ELVN Common Stock 394K Feb 6, 2024 See footnote F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 29, 2023.
F2 This transaction was executed in multiple trades at prices ranging from $15.07 to $15.11. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F3 The shares are held by The Patel / Dong Family Trust Dated August 24 2017 for which the Reporting Person serves as trustee.